NEW YORK, Aug. 01, 2019 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that management will present at the 39th Annual Canaccord Genuity Growth Conference in Boston on August 7th, 2019. The Company will present its corporate overview for 2019 with special focus on growth opportunities driven by advances in the science of cancer metabolism and clinical developments for its lead candidate SM-88 (racemetyrosine) in pancreatic, prostate and sarcoma cancers.
Event: 39th Annual Canaccord Genuity Growth Conference
Place: InterContinental, Boston
Presentation Date: August 7, 2019
Presentation Time: 4:00 PM ET; San Francisco Room
A live webcast of the presentation will be accessible on the events page under the Investor Relations section of Tyme Technologies’ website at www.tymeinc.com.
About Tyme Technologies
Tyme Technologies, Inc., is an emerging biotechnology company developing cancer therapeutics that are intended to be broadly effective across tumor types and have low toxicity profiles. Unlike targeted therapies that attempt to regulate specific mutations within cancer, the Company’s therapeutic approach is designed to take advantage of a cancer cell’s innate metabolic weaknesses to compromise its defenses, leading to cell death through oxidative stress and exposure to the body’s natural immune system. For more information, visit www.tymeinc.com. Follow us on social media: @tyme_Inc, LinkedIn, Instagram, Facebook and YouTube.
Forward-Looking Statements/Disclosure Notice
In addition to historical information, this press release contains forward-looking statements under the Private Securities Litigation Reform Act that involve substantial risks and uncertainties. The forward-looking statements contained in this press release are based on management's current expectations, which are subject to uncertainty, risks and changes in circumstances that are difficult to predict and many of which are outside of TYME's control. Factors that could cause actual results to differ materially from these forward-looking statements include the Company’s ability to successfully implement its clinical and other plans, competitive and regulatory developments, and the factors described in the section captioned “Risk Factors” of TYME’s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (“SEC”) on June 12, 2019, as well as subsequent reports and filings from time to time with the SEC.
The information contained in this press release is as of release date and TYME assumes no obligation to update forward-looking statements contained in this release as a result of future events or developments.
For Investor Relations & Media Inquiries: